Last updated: August 4, 2026
Moxifloxacin hydrochloride in 0.8% sodium chloride is a mature, hospital-focused generic intravenous fluoroquinolone, generally supplied as a 400 mg/250 mL premixed infusion in a flexible plastic container. Its commercial profile is driven by formulary access, hospital contracts, supply reliability and manufacturing cost rather than patent exclusivity. The original Avelox franchise lost meaningful U.S. exclusivity years ago, and current revenue is distributed across generic manufacturers, contract suppliers and hospital purchasing organizations.
The product has continuing clinical demand in selected adult bacterial infections, but its growth potential is limited by antimicrobial stewardship, generic price competition and substitution by other intravenous antibiotics.
What is moxifloxacin hydrochloride in sodium chloride 0.8%?
Moxifloxacin hydrochloride in sodium chloride injection is an intravenous formulation containing moxifloxacin hydrochloride equivalent to 400 mg of moxifloxacin in 250 mL of 0.8% sodium chloride. The product is administered by intravenous infusion and is typically packaged in a flexible plastic container.
The formulation is the injectable version of moxifloxacin, a fourth-generation fluoroquinolone with activity against selected Gram-positive, Gram-negative and atypical pathogens. U.S. labeling includes indications such as community-acquired bacterial pneumonia, complicated skin and skin-structure infections, and intra-abdominal infections, subject to current prescribing restrictions and boxed-warning requirements.[1]
Product characteristics
| Attribute |
Product profile |
| Active ingredient |
Moxifloxacin hydrochloride |
| Dosage form |
Intravenous solution |
| Typical strength |
400 mg/250 mL |
| Sodium chloride concentration |
0.8% |
| Container |
Flexible plastic infusion container |
| Primary buyers |
Hospitals, integrated delivery networks and group purchasing organizations |
| Prescription status |
Prescription-only |
| Regulatory category |
Abbreviated new drug application or legacy NDA product |
| Commercial maturity |
Mature generic |
| Primary competitors |
Generic moxifloxacin, levofloxacin, ciprofloxacin and other hospital antibiotics |
The plastic-container presentation reduces pharmacy compounding requirements and supports centralized hospital procurement. Product differentiation is limited because the active ingredient, dose and infusion volume are standardized.
What is the FDA regulatory status of intravenous moxifloxacin?
The reference product is Avelox, originally developed by Bayer and approved by the FDA in the late 1990s. Moxifloxacin injection was approved for intravenous use under the Avelox franchise after the oral product entered the market.[2]
Generic manufacturers obtained U.S. approvals after the principal patent and regulatory exclusivity barriers expired. FDA-approved generic products can be marketed when they demonstrate pharmaceutical equivalence and bioequivalence or meet the applicable requirements for injectable products.
The principal regulatory issues are:
- compliance with sterile manufacturing requirements;
- container-closure integrity;
- particulate and endotoxin control;
- stability of the premixed solution;
- compatibility with infusion equipment;
- labeling consistency with the reference product;
- compliance with fluoroquinolone safety warnings.
The FDA label includes serious warnings concerning tendinitis and tendon rupture, peripheral neuropathy, central nervous system effects, QT prolongation and other potentially disabling adverse reactions.[1] These warnings affect prescribing and can reduce use where narrower-spectrum or lower-risk alternatives are available.
What is the Orange Book status of moxifloxacin injection?
The historical Avelox patent estate is no longer a material barrier to generic intravenous moxifloxacin entry in the United States. The Orange Book historically identified patents covering moxifloxacin and related pharmaceutical forms. Those rights have expired or ceased to provide meaningful market exclusivity for the current product.[3]
| Exclusivity factor |
Current commercial effect |
| Core compound patents |
Expired |
| Formulation or solid-form patents |
Expired or no longer a practical barrier to standard IV entry |
| New chemical entity exclusivity |
Expired |
| Pediatric exclusivity |
Expired |
| Generic ANDA entry |
Established |
| Current patent moat |
Minimal for the standard 400 mg/250 mL product |
The product does not have the exclusivity profile of a recently approved branded injectable. A manufacturer’s competitive position depends on approval status, manufacturing capacity, inventory, quality history and contracting rather than control of an active patent.
When did moxifloxacin lose market exclusivity?
Moxifloxacin lost effective U.S. small-molecule exclusivity in the mid-2010s after expiration of the key patent and regulatory protections surrounding Avelox. Generic oral and injectable products subsequently entered the market.
A simplified exclusivity timeline is:
| Period |
Market event |
| 1999 |
FDA approval of Avelox in the United States |
| Early 2000s |
Expansion of the branded oral and intravenous franchise |
| 2010s |
Expiration of principal patent and regulatory exclusivity protections |
| Mid-2010s onward |
Generic ANDA competition expands |
| Current period |
Mature, multi-source hospital generic market |
The practical consequence was a rapid shift from branded pricing to institutional generic procurement. The timing of individual generic launches varied by dosage form, manufacturer and patent certifications.
Which companies manufacture or market moxifloxacin injection?
The U.S. market has included large generic injectable manufacturers and hospital-supply companies such as Baxter, Fresenius Kabi, Pfizer subsidiary Hospira, Sandoz, Hikma and other ANDA holders or contract manufacturers. Product availability varies by NDC, distributor inventory, manufacturing site and purchasing contract.
The commercial chain generally includes:
- API supplier;
- sterile injectable manufacturer;
- proprietary or contract-label marketer;
- wholesaler or group purchasing organization;
- hospital pharmacy or health-system customer.
Manufacturers with flexible plastic-container capacity have an operational advantage because hospitals often prefer ready-to-administer presentations. That advantage is manufacturing-based, not patent-based.
How important is the plastic container to market competition?
The container affects procurement and supply reliability more than clinical differentiation. Hospitals generally value:
- reduced preparation time;
- lower compounding labor;
- lower contamination risk;
- standardized infusion volumes;
- compatibility with automated pharmacy workflows;
- reliable shelf availability.
A manufacturer that can supply a consistent plastic-container product may win contracts even when competing products contain the same active ingredient and strength. However, container production, sterilization, filling and quality-control requirements raise the cost and complexity of entry relative to oral tablets.
How many patents cover moxifloxacin hydrochloride in sodium chloride injection?
No active U.S. patent estate creates a substantial barrier around the standard moxifloxacin 400 mg/250 mL premixed infusion. Historical patent activity focused on the active compound, chemical forms, pharmaceutical compositions and related manufacturing claims rather than a durable, commercially differentiated plastic-container system.
Potentially relevant rights may still arise from:
- container-closure systems;
- manufacturing processes;
- stability improvements;
- infusion-device interfaces;
- labeling or delivery technologies.
Those rights would need to be assessed at the product and manufacturer level. They do not recreate the broad exclusivity previously associated with the Avelox franchise.
Are there Paragraph IV challenges for moxifloxacin injection?
Paragraph IV litigation was relevant during the transition from Avelox to generic moxifloxacin. ANDA applicants could challenge listed patents by certifying that the patents were invalid, unenforceable or would not be infringed. Once the key patents expired, Paragraph IV risk declined sharply.
Current generic entrants face more conventional regulatory and commercial barriers:
- FDA approval timing;
- sterile manufacturing validation;
- product quality;
- supply commitments;
- hospital contracting;
- distributor onboarding;
- inventory and shortage management.
The main litigation risk for a new entrant is therefore less likely to involve the core moxifloxacin molecule and more likely to involve a specific formulation, manufacturing process, labeling position or contractual dispute.
What generic entry risks exist for moxifloxacin injection?
Generic entry risk is high because the product is technically established and the patent barrier is weak. Price pressure is strongest where several suppliers offer the same 400 mg/250 mL presentation.
Entry risks for incumbent manufacturers include:
- loss of formulary share after a contract rebid;
- price reductions demanded by group purchasing organizations;
- substitution by levofloxacin or other intravenous antibiotics;
- manufacturing shutdowns;
- shortages of sterile components or plastic containers;
- quality-related recalls;
- hospital preference for alternative broad-spectrum agents.
Entry risks for new manufacturers include the need to maintain sterile production at commercial scale. FDA approval alone does not guarantee meaningful market share. Hospitals frequently require validated supply continuity, adequate dating, reliable delivery and competitive contract pricing.
How does moxifloxacin injection compare with competing antibiotics?
Moxifloxacin competes primarily in hospital and emergency-care settings with levofloxacin, ceftriaxone-based regimens, piperacillin/tazobactam, ertapenem and other therapies selected according to infection type, local resistance patterns and stewardship policies.
| Product |
Main competitive advantage |
Main limitation |
| Moxifloxacin injection |
Broad activity and once-daily dosing |
Fluoroquinolone safety warnings and stewardship restrictions |
| Levofloxacin injection |
Broad hospital familiarity and extensive generic supply |
Similar fluoroquinolone safety concerns |
| Ceftriaxone |
Low acquisition cost and broad use in community-acquired infections |
Does not cover all atypical or resistant organisms |
| Piperacillin/tazobactam |
Broad Gram-negative and anaerobic coverage |
More frequent dosing and stewardship pressure |
| Ertapenem |
Convenient dosing and broad activity against selected pathogens |
Higher cost and narrower stewardship positioning |
Moxifloxacin can retain demand when once-daily dosing and atypical-pathogen coverage are valued. It loses share when hospitals prioritize lower cost, narrower spectrum or reduced fluoroquinolone exposure.
What is the financial trajectory for moxifloxacin hydrochloride in sodium chloride?
The financial trajectory follows a standard mature-generic pattern:
1. Branded expansion
During the Avelox period, the product benefited from brand pricing, physician promotion and broad clinical adoption. Revenue was generated across oral and intravenous formulations rather than the plastic-container presentation alone.
2. Patent-loss erosion
After generic entry, branded revenue declined as hospitals and payers substituted lower-cost products. The injectable presentation was especially exposed to institutional purchasing decisions.
3. Generic stabilization
The current market is characterized by lower unit prices, multiple suppliers and recurring hospital demand. Revenue is more stable in volume than in price. A manufacturer can generate acceptable returns through scale, supply reliability and contract discipline, but the product is unlikely to produce specialty-pharmaceutical margins.
4. Mature-market pressure
Long-term revenue is likely to remain flat to declining in nominal terms unless a manufacturer gains share through a supply disruption, wins a large institutional contract or expands distribution. Unit demand can remain resilient while revenue falls because of price erosion.
Public filings generally do not isolate revenue for the specific SKU "moxifloxacin hydrochloride in sodium chloride 0.8% in plastic container." Manufacturers report broader segments such as sterile injectables, hospital products or generic pharmaceuticals. Product-level financial analysis therefore depends on shipment volume, contract pricing, NDC sales data and procurement records rather than company-wide revenue disclosures.
Financial drivers
| Driver |
Effect on revenue |
| Number of approved suppliers |
Increases price pressure |
| Hospital contract wins |
Can materially increase volume |
| Supply shortages |
Can temporarily improve pricing |
| Fluoroquinolone stewardship |
Limits utilization |
| Plastic-container capacity |
Supports procurement access |
| API and packaging costs |
Affect gross margin |
| FDA quality actions |
Can cause rapid share loss |
| Alternative antibiotics |
Cap long-term growth |
What is the revenue exposure for generic manufacturers?
Revenue exposure is meaningful at the portfolio level but generally modest at the individual product level. Moxifloxacin injection can support a sterile-injectables portfolio because it uses established manufacturing infrastructure and serves recurring hospital demand. Its strategic value is greater when bundled with other injectable antibiotics in institutional contracts.
The product is unlikely to justify major standalone investment in a new manufacturing site. It can justify incremental capacity when a company already has:
- sterile liquid filling capability;
- plastic-container production or access to a qualified supplier;
- hospital distribution relationships;
- validated quality systems;
- a broader injectable portfolio.
Margins are vulnerable to a single additional supplier because the product has limited differentiation and no active compound exclusivity.
What manufacturing and intellectual-property barriers remain?
The principal barriers are operational rather than patent-based. A credible supplier must demonstrate:
- aseptic processing;
- validated sterilization controls;
- container integrity;
- stability through the labeled shelf life;
- control of visible and subvisible particles;
- reproducible assay and impurity profiles;
- commercial-scale batch release;
- continuity of API and packaging supply.
The plastic-container format can create supply bottlenecks if a manufacturer depends on a limited number of container suppliers. It can also create site-transfer and validation costs that slow replacement of an incumbent supplier.
What generic launch scenarios are most likely?
Three scenarios define the market:
Base case
Multiple suppliers remain active, pricing stays competitive and volume remains tied to hospital utilization. Revenue declines gradually through price pressure but does not collapse.
Upside case
A competitor experiences a manufacturing interruption, recall or shortage. Remaining suppliers gain temporary volume and may achieve improved pricing.
Downside case
Hospitals reduce fluoroquinolone use, substitute levofloxacin or non-fluoroquinolone regimens, and intensify contract price reductions. The product becomes a low-margin portfolio item.
Key Takeaways
- Moxifloxacin hydrochloride in 0.8% sodium chloride is a mature generic intravenous product, usually supplied as 400 mg/250 mL in a flexible plastic container.
- The principal Avelox patent and exclusivity barriers have expired, leaving little active patent protection around the standard presentation.
- Paragraph IV litigation is no longer the central market issue. Regulatory approval, sterile manufacturing and hospital contracting are more important.
- Revenue is driven by hospital volume, contract wins and supply reliability, while generic price erosion limits margin expansion.
- The plastic container provides procurement and workflow benefits but does not create strong product differentiation.
- Fluoroquinolone safety warnings and antimicrobial stewardship restrict long-term demand.
- The strongest commercial position belongs to manufacturers with validated sterile capacity, reliable supply and broad hospital portfolios.
- Product-level revenue is generally not disclosed separately by manufacturers, so financial performance is best evaluated through market share, NDC sales, contract volume and supply events.
FAQs about moxifloxacin hydrochloride in sodium chloride 0.8%
Is moxifloxacin injection still under patent protection?
No material U.S. patent barrier remains around the standard 400 mg/250 mL moxifloxacin premixed infusion. Historical compound and formulation protections have expired.
Is moxifloxacin injection a biologic or biosimilar product?
No. Moxifloxacin is a chemically synthesized small-molecule antibiotic. It is regulated through the generic drug pathway, not the biosimilar pathway.
Who buys moxifloxacin in a plastic container?
The primary buyers are hospitals, integrated health systems, outpatient infusion providers and institutional pharmacies. Group purchasing organizations often influence supplier selection.
Can a new manufacturer enter the moxifloxacin injection market?
Yes, subject to FDA approval, sterile manufacturing compliance, product-quality validation and commercial supply capability. Patent expiration reduces legal entry barriers, but hospital contracting and manufacturing scale remain significant obstacles.
What is the main commercial threat to moxifloxacin injection?
The main threat is substitution by other antibiotics combined with hospital price competition. Fluoroquinolone safety concerns and stewardship programs can reduce use even when generic supply remains available.
References
- U.S. Food and Drug Administration. (2024). Moxifloxacin hydrochloride injection prescribing information.
- U.S. Food and Drug Administration. (1999). Avelox NDA approval and prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- DailyMed. (2024). Moxifloxacin hydrochloride in sodium chloride injection product labeling. National Library of Medicine.
- U.S. Food and Drug Administration. (2018). Fluoroquinolone antibacterial drugs: Drug safety communication.
